SCReN is testing COMIRNATY vaccine in subjects received VAXZEVRIA

The condition is Covid19.

A new clinical trial is recruiting patients in the following locations: Spain.

The trial officially began on the April 24, 2021 and is planned to complete on April 30, 2022.

CombiVacS is a phase 2 randomized, adaptive trial developed to evaluate the immunogenicity of a dose of COMIRNATY after a previous single dose of VAXZEVRIA. A stratification will be made based on the following factors: study site, sex and age. This protocol allows to test the immunogenicity and safety of a heterologous vaccination strategy after a previous single dose of VAXZEVRIA.

Instituto de Salud Carlos III is the collaborator in this clinical trial.

The link to the complete study details, such as inclusion and exclusion criteria: https://ichgcp.net/clinical-trials-registry/NCT04860739

Clinical Research News

Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products
Submission of comments on ICH E6 (R3) Guideline for Good Clinical Practice(GCP) - Step 2b 
ICH E6(R3) Good Clinical Practice guidance - Step 2 Public Consultation
The study of the new investigational drug for acute myeloid leukemia and myelodysplastic syndrome
Open Label study of entrectinib in ROS1 gene fusion-positive rare adult, paediatric and teenage/young adult cancers
Gasherbrum Bio, Inc is starting the study of GSBR-1290 drug in overweight or obese healthy adults
A new study of Dexpramipexole in adolescents and adults with severe Eosinophilic Asthma

Tulevat kliiniset tutkimukset

SCReN is testing COMIRNATY vaccine in subjects received VAXZEVRIA

All jobs

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa